Clinico-pathological and genomic features of HER2-low early Breast Cancer (eBC). Results of retrospective analysis of seven adjuvant trials by the Hellenic Cooperative Oncology Group (HeCOG)

2025·

S. Lakis

,

E. Tsolaki

Nikolaos Korfiatis

,

A. Goussia

,

H.P. Kourea

,

A. Batistatou

,

M. Bobos

,

K. Papadopoulou

,

A. Charchanti

,

M. Bai

,

O. Tzaida

,

K. Petraki

,

P. Arapantoni

,

T. Koletsa

,

D. Pectasides

,

A. Koutras

,

D. Kalapanida

,

F. Dimitrakopoulos

,

E. Aravantinou-Fatorou

,

N. Spathas

,

A. Psyrri

,

H. Gogas

,

F. Zagouri

,

G. Fountzilas

NCT07561346 Cite DOI

Conference Paper Clinical Trial

Authors

Nikolaos Korfiatis

Professor of Data Management and Analytics

Professor of Data Management and Analytics at the Department of Informatics, Ionian University, Corfu. Senior Statistician of the Hellenic Cooperative Oncology Group (HeCOG).

---

← Clinical outcomes and important prognostic biomarkers following dose-dense sequential adjuvant chemotherapy (dds-CT) in early breast cancer (eBC): Pooled-analysis of individual patient data 2025

Detection of germline and somatic pathogenic variants in patients with de novo metastatic breast cancer (dnMBC) and assessment of their prognostic relevance: A Hellenic Cooperative Oncology Group (HeCOG) translational cohort study 2025 →